Onwordi, Ellis Chika http://orcid.org/0000-0001-8108-1225
Whitehurst, Thomas http://orcid.org/0000-0002-7005-902X
Mansur, Ayla
Statton, Ben http://orcid.org/0000-0001-5118-7977
Berry, Alaine
Quinlan, Marina
O’Regan, Declan P. http://orcid.org/0000-0002-0691-0270
Rogdaki, Maria http://orcid.org/0000-0003-2685-1789
Marques, Tiago Reis http://orcid.org/0000-0003-0602-7661
Rabiner, Eugenii A. http://orcid.org/0000-0003-3612-6687
Gunn, Roger N.
Vernon, Anthony C. http://orcid.org/0000-0001-7305-1069
Natesan, Sridhar http://orcid.org/0000-0001-7499-1714
Howes, Oliver D. http://orcid.org/0000-0002-2928-1972
Article History
Received: 21 February 2021
Accepted: 22 June 2021
First Online: 17 July 2021
Competing interests
: AM, EAR and RNG are employees of Invicro LLC. RNG is a consultant for AbbVie, Biogen & Cerveau. TRM has received honoraria for speaking and chairing from Lundbeck, Jansenn and Astellas, and received honoraria to participate in advisory boards organised by Angelini Pharmaceuticals. ODH is a part-time employee of H Lundbeck A/v and has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, Astra-Zeneca, Autifony, Biogen, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither ODH nor his family have holdings/a financial stake in any pharmaceutical company. The other authors declare no competing interests. The opinions expressed in this study are solely those of the authors and should not be taken as representing those of the NIHR, NHS, Lundbeck or any other organisation.